Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

Hypertension Clinical Trial

— SEAIRA  

Official title:

Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00980785
• Other study ID #: 2014-1353
• Secondary ID: H-2009-0036A5342
• Status: Completed
• Phase: Phase 4
• Start date: April 9, 2009
• Est. completion date: July 26, 2011

Study information

• Verified date: August 2020
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The purpose of the research is to see how ramipril affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting Alzheimer's disease. This study will see if ramipril can lower the amount of beta-amyloid in the spinal fluid. This study will also see if ramipril affects blood vessel function and memory and thinking. The investigators hope that future studies will show whether ramipril might prevent memory loss and decrease the chance of developing Alzheimer's disease.

Description:

High blood pressure (BP) in midlife is predictive of Alzheimer's disease (AD) in later life. Similarly, reductions in BP are associated with protection against AD. Treatment with antihypertensive medications, specifically angiotensin converting enzyme inhibitors (ACE-I) such as ramipril, is associated with up to a 55% reduction in the prevalence of AD, suggesting a potentially promising role for ACE-I in the prevention of AD. It is unknown however 1) whether ACE-Is will have the same effect on Cerebrospinal fluid (CSF) Aβ levels in humans as in animal models 2) whether ACE-Is induce changes associated with vascular function (i.e. levels of CSF angiotensin converting enzyme (ACE) and peripheral endothelial function) and 3) whether there are interactions between ACE-I-induced changes in CSF Aβ, CSF ACE and indices of vascular function.

One mechanism by which antihypertensives may protect against AD is via Aβ neuropathology. In order to better understand the mechanisms through which ACE-I may modify CSF Aβ and possibly AD risk, we propose a randomized, double-blind, placebo-controlled pilot clinical trial, enrolling 20 middle-aged (age range 40 - 65 years), mildly hypertensive (between 130 - 160 mmHg mean systolic and between 85 - 100 mmHg mean diastolic) participants, who are adult children of an individual with AD. The main objective of this trial is to examine the effects of the ACE-I, ramipril, on 1) CSF Aβ levels 2) CSF ACE levels and 3) peripheral endothelial function as measured by brachial artery flow-mediated vasodilation (FMD) and aortic augmentation index (AAIx), in middle-aged adults with mildly elevated BP, who are at increased risk of developing AD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: July 26, 2011
• Est. primary completion date: July 26, 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Between the ages of 40 and 65

• Mean resting blood pressure between 130-160 systolic and 85-100 diastolic

• Parent with Alzheimer's Disease

Exclusion Criteria:

• Current involvement in another investigational drug trial.

• Potassium > 5.0

• Dementia based on DSMIV criteria

• Mini-Mental State Exam (MMSE) score < 27

• Current blood pressure medication (< 4 months from screening)

• Weight loss medication

• Contraindications for LP

• Know diagnosis or history of hospitalization due to congestive heart failure

• Elevated creatinine (females > 1.3 mg/dL or males > 1.4 mg/dL at baseline)

• Diabetes Type I and II

• Know adverse reaction to an ACE-I or an angiotensin receptor blocker

• Pregnant of nursing women

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Hypertension

Intervention

Drug:
• Ramipril
Ramipril 5 mg/day
• Placebo
Matching Placebo

Locations

Country	Name	City	State
United States	Wisconisn Alzheimer's Disease Research Center	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wharton W, Stein JH, Korcarz C, Sachs J, Olson SR, Zetterberg H, Dowling M, Ye S, Gleason CE, Underbakke G, Jacobson LE, Johnson SC, Sager MA, Asthana S, Carlsson CM. The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. J Alzheimers Dis. 2012;32(1):147-56. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Cerebrospinal Fluid (CSF) Amyloid Beta-42 (Aß42) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo	CSF Aß42 levels will be measured from the cerebrospinal fluid taken from subjects on ramipril or placebo at the baseline visit and month 4 and will be measured by Dr. Henrik Zetterberg's laboratory.	Baseline to 4 months
Secondary	Change in CSF Angiotensin Converting Enzyme (ACE) Levels Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo	CSF ACE levels will be measured from the cerebrospinal fluid taken from subjects on Ramipril or placebo at the baseline visit and month 4 and will be measured by ARUP® laboratories by spectrophotometric enzymatic assay.	Baseline to 4 months
Secondary	Change in Flow-mediated Vasodilation (FMD) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo	FMD is calculated as the ratio of brachial artery diameter after reactive hyperemia to baseline diameter, expressed as percentage change. FMD for each subject (ramipril v placebo) will be measured at baseline and month 4, observing any differences.	Baseline to 4 months
Secondary	Change in Augmentation Index (%) Between Baseline and Month 4 in Subjects Taking Ramipril vs Subjects on Placebo	Pulse wave velocity was measured using an AtCor SphymoCor Px tonometry system. A small pressure transducer was placed on the skin at the point the arterial pulsation of the right common carotid and right radial arteries. A Millar micromanometer is in the tip of the probe. Using a generalized transfer function, the distance between these pressure points, and the peripheral arterial waveforms, a central aortic pressure signal is derived, from which aortic augmentation index is determined.	Baseline to 4 months

External Links

•   Related Info
•   The Effects of Ramipril in Individuals at Risk for Alzheimer's Disease: Results of a Pilot Clinical Trial